JP6403219B2 - ベータ−ラクタマーゼ阻害剤 - Google Patents

ベータ−ラクタマーゼ阻害剤 Download PDF

Info

Publication number
JP6403219B2
JP6403219B2 JP2015545855A JP2015545855A JP6403219B2 JP 6403219 B2 JP6403219 B2 JP 6403219B2 JP 2015545855 A JP2015545855 A JP 2015545855A JP 2015545855 A JP2015545855 A JP 2015545855A JP 6403219 B2 JP6403219 B2 JP 6403219B2
Authority
JP
Japan
Prior art keywords
optionally substituted
acid
alkyl
formula
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015545855A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016502973A5 (enExample
JP2016502973A (ja
Inventor
バーンズ，クリストファー，ジェイ．
デイグル，デニス
リウ，ビン
マクギャリー，ダニエル
シー． ペビアー，ダニエル
シー． ペビアー，ダニエル
イー．リー トラウト，ロバート
イー．リー トラウト，ロバート
Original Assignee
ベナトルクス ファーマシューティカルズ，インク．
ベナトルクス ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベナトルクス ファーマシューティカルズ，インク．, ベナトルクス ファーマシューティカルズ，インク． filed Critical ベナトルクス ファーマシューティカルズ，インク．
Publication of JP2016502973A publication Critical patent/JP2016502973A/ja
Publication of JP2016502973A5 publication Critical patent/JP2016502973A5/ja
Application granted granted Critical
Publication of JP6403219B2 publication Critical patent/JP6403219B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2015545855A 2012-12-07 2013-12-05 ベータ−ラクタマーゼ阻害剤 Active JP6403219B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261734900P 2012-12-07 2012-12-07
US61/734,900 2012-12-07
US201361783238P 2013-03-14 2013-03-14
US61/783,238 2013-03-14
PCT/US2013/073428 WO2014089365A1 (en) 2012-12-07 2013-12-05 Beta-lactamase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018114967A Division JP2018184409A (ja) 2012-12-07 2018-06-15 ベータ−ラクタマーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2016502973A JP2016502973A (ja) 2016-02-01
JP2016502973A5 JP2016502973A5 (enExample) 2016-12-01
JP6403219B2 true JP6403219B2 (ja) 2018-10-10

Family

ID=50884012

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015545855A Active JP6403219B2 (ja) 2012-12-07 2013-12-05 ベータ−ラクタマーゼ阻害剤
JP2018114967A Pending JP2018184409A (ja) 2012-12-07 2018-06-15 ベータ−ラクタマーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018114967A Pending JP2018184409A (ja) 2012-12-07 2018-06-15 ベータ−ラクタマーゼ阻害剤

Country Status (16)

Country Link
US (6) US9422314B2 (enExample)
EP (2) EP2928898B1 (enExample)
JP (2) JP6403219B2 (enExample)
KR (1) KR102147420B1 (enExample)
CN (1) CN105026407B (enExample)
AU (1) AU2013355110B2 (enExample)
BR (1) BR112015013123B1 (enExample)
CA (1) CA2893943C (enExample)
ES (1) ES2878118T3 (enExample)
HR (1) HRP20210879T1 (enExample)
IL (1) IL239212B (enExample)
PL (1) PL2928898T3 (enExample)
PT (1) PT2928898T (enExample)
RU (1) RU2654692C2 (enExample)
WO (1) WO2014089365A1 (enExample)
ZA (1) ZA201504200B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017518991A (ja) * 2014-06-11 2017-07-13 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
JP2018184409A (ja) * 2012-12-07 2018-11-22 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6266978B2 (ja) 2010-08-10 2018-01-24 レンペックス・ファーマシューティカルズ・インコーポレイテッド 環状ボロン酸エステル誘導体およびその治療的使用
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2014107536A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
BR112015016001A2 (pt) * 2013-01-04 2017-07-11 Rempex Pharmaceuticals Inc compostos, composições farmacêuticas e respectivos usos e método para tratar ou prevenir infecção bacteriana
CN105101970B (zh) 2013-01-10 2018-11-20 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
PL3604316T3 (pl) 2014-05-05 2024-04-29 Melinta Therapeutics, Inc. Synteza soli boronianowych
EP3139930B1 (en) 2014-05-05 2024-08-14 Melinta Therapeutics, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
US9963467B2 (en) 2014-05-19 2018-05-08 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US20150361108A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR20170024087A (ko) * 2014-07-01 2017-03-06 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3233869B1 (en) 2014-12-19 2019-09-25 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
CA2971763A1 (en) 2014-12-23 2016-06-30 Bergenbio Asa Inhibitors of akt kinase
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2017044828A1 (en) * 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) * 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
PT3478693T (pt) * 2016-06-30 2021-10-25 Qpex Biopharma Inc Derivados de ácido borónico e suas utilizações terapêuticas
EP3494121B1 (en) 2016-08-04 2021-10-06 Venatorx Pharmaceuticals, Inc. Boron-containing compounds
GB201613946D0 (en) * 2016-08-15 2016-09-28 Univ Oslo Compounds
CA3055253A1 (en) * 2017-03-06 2018-09-13 VenatoRx Pharmaceuticals, Inc. Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
WO2018199291A1 (ja) * 2017-04-28 2018-11-01 大日本住友製薬株式会社 ヘテロ環誘導体
GB201708002D0 (en) 2017-05-18 2017-07-05 Univ Oxford Innovation Ltd ß-Lactamase inhibitors
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CA3078627A1 (en) 2017-10-11 2019-04-18 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
CN118388347A (zh) 2017-11-01 2024-07-26 梅琳塔治疗公司 化合物、由其形成的硼酸酯衍生物及其制备方法
EP3781576B1 (en) 2018-04-20 2024-06-12 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
KR102679411B1 (ko) * 2018-04-27 2024-07-01 스미토모 파마 가부시키가이샤 옥소 치환 화합물
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2020056048A1 (en) 2018-09-12 2020-03-19 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor
SG11202110683WA (en) * 2019-04-02 2021-10-28 Venatorx Pharmaceuticals Inc Solid forms of an orally-delivered beta-lactamase inhibitor and uses thereof
JP7550421B2 (ja) * 2019-10-25 2024-09-13 住友ファーマ株式会社 オキソ置換化合物からなる医薬
MX2022004912A (es) 2019-10-25 2022-08-25 Sumitomo Pharma Co Ltd Novedoso compuesto de anillo condensado sustituido.
US11058695B2 (en) * 2019-11-08 2021-07-13 Myongji University Industry And Academia Cooperation Foundation Inhibitor of carbapenem-hydrolyzing class D beta-lactamases
TW202128718A (zh) 2019-11-26 2021-08-01 美商維納拓爾斯製藥公司 青黴素結合蛋白抑制劑
EP4201942A4 (en) * 2020-08-20 2024-08-21 Phaeno Therapeutics Co., Ltd. BORACIC ACID COMPOUND
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
WO2022187362A1 (en) * 2021-03-02 2022-09-09 Case Western Reserve University Β-lactamase inhibitors and uses thereof
MX2023012004A (es) 2021-04-13 2023-10-20 Tuojie Biotech Shanghai Co Ltd DERIVADO DEL ÁCIDO BÓRICO QUE ACTÚA COMO INHIBIDOR DE LA ß-LACTAMASA.
WO2023155869A1 (zh) * 2022-02-18 2023-08-24 辉诺生物医药科技（杭州）有限公司 新的硼酸类化合物的晶型及其制备方法
GB202306835D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE41109B1 (en) 1974-04-20 1979-10-24 Beecham Group Ltd Novel -lactam antibiotic from streptomyces clavuligerus
IT1283467B1 (it) * 1996-07-19 1998-04-21 Menarini Farma Ind Derivati di cicloalcani 1,2 sostituiti come inibitori della trombina, procedimento per la loro preparazione e loro impiego in formulazioni
CA2385747A1 (en) 1999-09-17 2001-03-22 Gavin C. Hirst Pyrazolopyrimidines as therapeutic agents
US7271186B1 (en) * 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
US7183267B2 (en) 2003-06-10 2007-02-27 The Johns Hopkins University β-lactamase inhibitors and methods of use thereof
SI1756121T1 (sl) 2004-03-30 2012-03-30 Millennium Pharm Inc Sinteza estra borove kisline in kislinske spojine
CN1965838A (zh) 2005-11-17 2007-05-23 李海超 含头孢匹胺和β－内酰胺酶抑制剂的药物组合物
SI1965798T1 (sl) 2005-12-07 2012-01-31 Basilea Pharmaceutica Ag Uporabni monobaktamski antibiotiki
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
MX2010005250A (es) * 2007-11-13 2010-11-05 Novartis Int Pharm Ltd Inhibidores de beta-lactamasa.
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
PT2666774E (pt) * 2008-01-18 2015-04-13 Merck Sharp & Dohme Inibidores de beta-lactamase
AR076667A1 (es) 2009-05-12 2011-06-29 Novartis Int Pharm Ltd Inhibidores de beta-lactamasa
RU2012107163A (ru) 2009-07-28 2013-09-10 Анакор Фармасьютикалз, Инк. Тризамещенные борсодержащие молекулы
JP6266978B2 (ja) 2010-08-10 2018-01-24 レンペックス・ファーマシューティカルズ・インコーポレイテッド 環状ボロン酸エステル誘導体およびその治療的使用
NZ617104A (en) 2011-07-26 2015-05-29 Wockhardt Ltd Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
SG11201400293UA (en) 2011-09-04 2014-08-28 Glytech Inc Glycosylated polypeptide and drug composition containing said polypeptide
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
KR101288157B1 (ko) 2011-12-07 2013-07-19 백병하 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제
JP6129203B2 (ja) 2011-12-22 2017-05-17 アレス トレーディング ソシエテ アノニム α−アミノボロン酸誘導体、選択性免疫プロテアソーム阻害剤
WO2013122888A2 (en) 2012-02-15 2013-08-22 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
MX2015006715A (es) 2012-12-03 2015-08-14 Hoffmann La Roche Compuestos de acido triazolboronico sustituido.
EP2928898B1 (en) 2012-12-07 2021-04-14 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2014107536A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
BR112015016001A2 (pt) 2013-01-04 2017-07-11 Rempex Pharmaceuticals Inc compostos, composições farmacêuticas e respectivos usos e método para tratar ou prevenir infecção bacteriana
CN105101970B (zh) * 2013-01-10 2018-11-20 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
WO2015157618A1 (en) 2014-04-11 2015-10-15 The Texas A&M University System Novel inhibitors of the new delhi metallo beta lactamase (ndm-1)
US9963467B2 (en) 2014-05-19 2018-05-08 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2015191907A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20150361107A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
US20150361108A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
WO2016035846A1 (ja) 2014-09-04 2016-03-10 塩野義製薬株式会社 カテコール基を有するセファロスポリン類を含有する製剤
EP3233869B1 (en) 2014-12-19 2019-09-25 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
EP3494121B1 (en) 2016-08-04 2021-10-06 Venatorx Pharmaceuticals, Inc. Boron-containing compounds
CA3055253A1 (en) 2017-03-06 2018-09-13 VenatoRx Pharmaceuticals, Inc. Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2019118358A1 (en) 2017-12-11 2019-06-20 VenatoRx Pharmaceuticals, Inc. Hepatitis b capsid assembly modulators
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018184409A (ja) * 2012-12-07 2018-11-22 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
JP2017518991A (ja) * 2014-06-11 2017-07-13 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤

Also Published As

Publication number Publication date
US20140171390A1 (en) 2014-06-19
ES2878118T3 (es) 2021-11-18
US9422314B2 (en) 2016-08-23
KR102147420B1 (ko) 2020-08-25
IL239212B (en) 2019-10-31
CA2893943C (en) 2021-03-02
US20150291630A1 (en) 2015-10-15
KR20150109348A (ko) 2015-10-01
RU2015126912A (ru) 2017-01-12
US20250236632A1 (en) 2025-07-24
WO2014089365A1 (en) 2014-06-12
US20160326189A1 (en) 2016-11-10
EP2928898A4 (en) 2016-06-29
HRP20210879T1 (hr) 2021-08-20
EP2928898B1 (en) 2021-04-14
CN105026407B (zh) 2017-09-08
RU2654692C2 (ru) 2018-05-22
BR112015013123B1 (pt) 2021-02-17
CA2893943A1 (en) 2014-06-12
AU2013355110B2 (en) 2017-11-09
PL2928898T3 (pl) 2021-10-25
US8912169B2 (en) 2014-12-16
PT2928898T (pt) 2021-07-05
AU2013355110A1 (en) 2015-07-02
HK1217334A1 (zh) 2017-01-06
US10669290B2 (en) 2020-06-02
JP2016502973A (ja) 2016-02-01
IL239212A0 (en) 2015-07-30
US9828391B2 (en) 2017-11-28
EP3922635A1 (en) 2021-12-15
BR112015013123A2 (pt) 2017-07-11
US20190225628A1 (en) 2019-07-25
US20180194783A1 (en) 2018-07-12
JP2018184409A (ja) 2018-11-22
ZA201504200B (en) 2017-09-27
US10214547B2 (en) 2019-02-26
CN105026407A (zh) 2015-11-04
EP2928898A1 (en) 2015-10-14

Similar Documents

Publication Publication Date Title
JP6403219B2 (ja) ベータ−ラクタマーゼ阻害剤
US11414435B2 (en) Beta-lactamase inhibitors
HK1217334B (en) Beta-lactamase inhibitors
HK1217446B (zh) β-内酰胺酶抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161012

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170920

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180615

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180906

R150 Certificate of patent or registration of utility model

Ref document number: 6403219

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250